Proliferation and glycolytic capacity of metastatic melanoma cells were found to decrease when expression of B7-H3 was reduced or inhibited, leading to reduced resistance to chemotherapy as well as other targeted therapies 39; this mechanism was further demonstrated to involve the inactivation of p38 MAPK signaling 40. This evidence concerns the gene CD276 and melanoma.